Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Opdivo
Opdivo
AZ chief: Durvalumab's ready for a 'marketing battle' against I-O heavyweights Opdivo, Keytruda
Fierce Pharma
Tue, 02/7/17 - 10:25 am
immuno-oncology
AstraZeneca
durvalumab
Pascal Soriot
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
FDA approves Bristol-Myers' Opdivo for bladder cancer
Yahoo/Reuters
Fri, 02/3/17 - 10:13 am
FDA
Bristol-Myers Squibb
Opdivo
bladder cancer
Merck Makes Nice With Bristol-Myers Squibb
Motley Fool
Tue, 01/31/17 - 10:07 am
Merck
Bristol-Myers Squibb
patents
Keytruda
Opdivo
Roche cancer drug taking bite out of Bristol's Opdivo
Yahoo/Reuters
Fri, 01/27/17 - 09:23 am
Roche
Bristol-Myers Squibb
Tecentriq
non-small cell lung cancer
Opdivo
Merck to pony up $625M plus Keytruda royalties to settle BMS, Ono patent fight
Fierce Pharma
Mon, 01/23/17 - 11:11 am
Merck
Keytruda
Bristol-Myers Squibb
Ono Pharmaceutical
Opdivo
patents
Bristol-Myers shares drop after company says it will not seek fast-track drug approval
CNBC
Sat, 01/21/17 - 11:52 am
Bristol-Myers Squibb
fast track
lung cancer
Opdivo
Yervoy
Bristol-Myers Falls Further Behind Merck in Lung Cancer Race
Bloomberg
Thu, 01/19/17 - 11:32 pm
Bristol-Myers Squibb
Merck
lung cancer
Keytruda
Opdivo
Why Bristol-Myers Squibb May Be a Merger Target Soon
TheStreet.com
Tue, 01/17/17 - 11:03 am
Bristol-Myers Squibb
M&A
Opdivo
2 Big Reasons Merck & Co., Inc. Stock Surged 11% in 2016
Motley Fool
Sun, 01/8/17 - 03:18 pm
Merck
Keytruda
Opdivo
Bristol-Myers Squibb
3 Biggest Risks for Bristol-Myers Squibb in 2017
Motley Fool
Sun, 01/1/17 - 11:36 am
Bristol-Myers Squibb
Opdivo
Abilify
Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016
Market Realist
Thu, 12/22/16 - 10:23 am
Opdivo
Bristol-Myers Squibb
The Year In Review: Merck Can Look Back And Smile
Forbes
Tue, 12/13/16 - 10:17 am
Merck
Keytruda
Opdivo
Bristol-Myers Squibb
Gardasil
How Did Bristol-Myers Squibb’s Blockbuster Oncology Drug Perform?
Market Realist
Mon, 11/28/16 - 09:43 am
Opdivo
Bristol-Myers Squibb
Bristol’s Opdivo Has One Eye on Advanced Bladder Cancer
Market Realist
Tue, 11/22/16 - 11:29 am
Bristol-Myers Squibb
Opdivo
bladder cancer
Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class
Market Realist
Mon, 11/21/16 - 11:39 am
AstraZeneca
anti-PD-L1
durvalumab
Opdivo
Keytruda
Tecentriq
Bristol-Myers Squibb
Roche
Merck
Understanding Bristol’s Blockbuster: Opdivo’s Edge over Keytruda
Market Realist
Sat, 11/19/16 - 11:17 am
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
Japan sets 50 pct price cut for Bristol Myers' Opdivo cancer drug
Yahoo/Reuters
Thu, 11/17/16 - 09:47 am
Japan
Bristol-Myers Squibb
Opdivo
drug pricing
non-small cell lung cancer
Bristol's Bid To Get Ahead In Head And Neck
Seeking Alpha
Tue, 11/15/16 - 09:17 am
Bristol-Myers Squibb
head and neck cancer
Opdivo
Keytruda
Merck
Bristol-Myers' Opdivo succeeds in key stomach cancer study
Yahoo/Reuters
Thu, 11/10/16 - 11:02 am
Bristol-Myers Squibb
Opdivo
stomach cancer
Some Immuno-Oncology Drugs Carry Risk of Rare Heart Damage
Xtalks
Mon, 11/7/16 - 09:17 pm
immuno-oncology
heart damage
Opdivo
Yervoy
Bristol-Myers Squibb
anti-PD-1 immunotherapy
Pages
« first
‹ previous
…
9
10
11
12
13
14
15
16
17
…
next ›
last »